STAAR Surgical Announces Strategic Agreement With IQ Laser Vision In U.S.
Portfolio Pulse from Benzinga Newsdesk
STAAR Surgical Company (NASDAQ:STAA) has entered into a strategic agreement with IQ Laser Vision, marking a significant commitment to the EVO ICL product in the U.S. This partnership aims to make EVO ICL lenses a primary option for surgical vision correction, intending to nearly double the volume of EVO ICLs within the next 12 months. The collaboration will include marketing, education, and clinical support to increase awareness and availability of EVO ICL across IQ Laser Vision's practices. STAAR Surgical's CEO, Tom Frinzi, highlighted the agreement as a milestone in the U.S. Highway 93 go-to-market program and a step towards establishing lens-based procedures as the future of refractive vision correction.
May 07, 2024 | 8:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
STAAR Surgical's strategic agreement with IQ Laser Vision is expected to significantly increase the volume and awareness of EVO ICL lenses in the U.S., positioning the company at the forefront of refractive vision correction.
The agreement with IQ Laser Vision, a leader in refractive eye surgery, to make EVO ICL lenses a primary option for patients, coupled with plans to nearly double the volume of EVO ICLs, indicates a strong potential for increased sales and market penetration for STAAR Surgical. This strategic move is likely to enhance STAAR's position in the market and could lead to positive investor sentiment, driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100